Welcome to our dedicated page for iRhythm Holdings news (Ticker: IRTC), a resource for investors and traders seeking the latest updates and insights on iRhythm Holdings stock.
iRhythm Technologies, Inc. (NASDAQ: IRTC) generates frequent news as a digital health care company focused on long-term ambulatory cardiac monitoring and data-driven arrhythmia detection. News coverage commonly highlights clinical study results, financial performance, product-related updates for the Zio long-term continuous monitoring (LTCM) service, and the company’s participation in major medical and investor conferences.
Many announcements center on real-world evidence and clinical research. iRhythm regularly reports data from large-scale analyses and trials such as CAMELOT, AVALON, AMALFI, and studies presented at the American Heart Association Scientific Sessions, the Asia Pacific Heart Rhythm Society meetings, and other scientific forums. These updates often explore topics like diagnostic yield compared with other monitoring modalities, performance in diverse patient populations, home-based self-application of Zio devices, and earlier arrhythmia detection in at-risk groups, including those with cardio-kidney-metabolic or chronic kidney disease profiles.
Investors and clinicians following IRTC news will also find quarterly earnings releases, guidance updates, and commentary on operational trends in the company’s core Zio LTCM business, mobile cardiac telemetry initiatives, and international expansion. Additional items include information on investor presentations at healthcare conferences and updates on corporate policies or governance disclosed through press releases linked to SEC filings.
This news page aggregates these developments in one place, allowing readers to review iRhythm’s latest clinical evidence, business updates, and strategic commentary over time. For those tracking digital health, ambulatory ECG monitoring, and AI-enabled cardiac diagnostics, the IRTC news feed provides ongoing insight into how the company presents its technology, research findings, and market priorities.
iRhythm (NASDAQ:IRTC) provided preliminary Q4 2025 highlights and a business update at the 44th Annual J.P. Morgan Healthcare Conference. The company expects full‑year 2025 revenue to exceed the high end of prior guidance of $740 million, driven by record revenue unit volume in Q4 2025. For full‑year 2026, iRhythm projects revenue of $870–$880 million (approximately 17%–18% YoY) and an adjusted EBITDA margin of ~11.5%–12.5%. Management cited clinical evidence from >1.4 million patients supporting Zio long‑term continuous monitoring and noted free cash flow positivity in 2025. Management presented on Jan 12, 2026 at 8:15 AM PT; a live and archived webcast is available on the company investor site.
iRhythm Technologies (NASDAQ:IRTC) will present at the 44th Annual J.P. Morgan Healthcare Conference.
Management is scheduled to present on Monday, January 12, 2026 at 8:15 a.m. PT / 11:15 a.m. ET. A live and archived webcast will be available in the Events and Presentations section of the company investor website at investors.irhythmtech.com.
iRhythm Technologies (NASDAQ:IRTC) presented a large-scale analysis of 408,470 U.S. patients at APHRS 2025 showing consistent performance of the Zio® long-term continuous ECG monitoring (LTCM) system across Asian and non-Asian groups.
Key metrics: Asians were 3.4% of the cohort; median wear time 13.6 vs. 13.0 days; analyzable ECG 12.9 vs. 12.2 days; AF detection 14.0% vs. 14.3%; total arrhythmia yield 79.8% vs. 82.9%; repeat testing 14.8% vs. 15.4%. Findings support generalizability of Zio LTCM and note AI algorithm approval by PMDA for Japan use.
iRhythm Technologies (NASDAQ: IRTC) announced publication of a large real-world study in Heart Rhythm and new data presented at AHA Scientific Sessions 2025.
The Heart Rhythm analysis of >1.1 million Zio long‑term continuous monitoring (LTCM) patients found that 24–48 hour monitoring missed actionable arrhythmias (64% of daily‑symptom patients with actionable arrhythmias were undetected in the first 48 hours) and that mean time to first arrhythmia exceeded 48 hours for all arrhythmia types; symptom–rhythm correlation was 20%. AHA data across >742,000 Zio devices showed home self‑application achieved median wear >13.8 days and >98% analyzable ECG time, and CKM/CKD analyses across >10 million patients revealed earlier arrhythmia emergence across disease stages.
iRhythm Technologies (NASDAQ: IRTC) announced management will present at four investor conferences in November–December 2025.
Scheduled presentations: Wolfe Research on Nov 18, 2025 at 9:20 AM ET; Jefferies on Nov 20, 2025 at 9:30 AM GMT; Citi on Dec 3, 2025 at 1:00 PM ET; and Evercore on Dec 4, 2025 at 9:10 PM ET. Live and archived webcasts will be available in the Events & Presentations section of the company investor website at investors.irhythmtech.com.
iRhythm (NASDAQ: IRTC) reported Q3 2025 revenue of $192.9M, up 30.7% YoY, and gross margin of 71.1% (+230 bps YoY). The company reported a Q3 2025 net loss of $5.2M (diluted loss $0.16) and an adjusted net loss of $2.0M (diluted loss $0.06), both substantially improved versus Q3 2024. Unrestricted cash, cash equivalents, and marketable securities were $565.2M as of September 30, 2025. Management increased full-year 2025 guidance to $735M–$740M revenue with an adjusted EBITDA margin of ~8.25%–8.75%. Company cited clinical publications and FDA submission activity for next-gen Zio MCT.
iRhythm Technologies (NASDAQ:IRTC) announced it will release third quarter 2025 financial results after market close on Thursday, October 30, 2025. Management will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET the same day.
Investors and interested parties can access a live and archived webcast of the call on the company’s Quarterly Results investor website at investors.irhythmtech.com.
iRhythm Technologies (NASDAQ:IRTC) announced significant results from the Oxford University-led AMALFI randomized clinical trial, presented at ESC Congress 2025 and published in JAMA. The study evaluated home-based screening for atrial fibrillation using iRhythm's Zio long-term continuous monitoring (LTCM) service.
The trial, involving 5,040 participants aged ≥65 in the UK, demonstrated that Zio LTCM led to increased AFib detection (6.8% vs 5.4% in control group) and significantly faster diagnosis (103 days vs 530 days). Participants using Zio showed higher oral anticoagulation prescription rates, with 1.63 months exposure compared to 1.14 months in the control group.
The study validated the effectiveness of home-based, self-applied monitoring, with participants achieving a median wear time of 13.9 days and 98.8% analyzable time, despite the higher comorbidity burden of the study population.
iRhythm Technologies (NASDAQ:IRTC), a digital health care company specializing in disease detection and prediction solutions, has announced its participation in three upcoming investor conferences in September 2025.
The company will present at the Wells Fargo Healthcare Conference on September 3 at 12:45 PM ET, the Morgan Stanley Global Healthcare Conference on September 9 at 2:35 PM ET, and the Baird Global Healthcare Conference on September 10 at 12:50 PM ET. Webcasts will be available on the company's investor relations website.
iRhythm Technologies (NASDAQ:IRTC) announced groundbreaking results from the AVALON study, the largest real-world evaluation of ambulatory cardiac monitoring involving 428,707 commercially insured patients. The study, published in the American Journal of Managed Care, demonstrates the clinical superiority of iRhythm's Zio long-term continuous monitoring (LTCM) service.
The Zio LTCM service showed remarkable advantages over competitors, achieving the highest diagnostic yield (26.5%) compared to other monitoring services, fastest time to diagnosis (9 days), and lowest total healthcare costs ($10,476 per patient-year). The study revealed that Zio LTCM was up to 2.04 times more likely to diagnose arrhythmias compared to Holter monitors and demonstrated the lowest retest rate of 3.1% within 180 days.
FAQ
What is the current stock price of iRhythm Holdings (IRTC)?
What is the market cap of iRhythm Holdings (IRTC)?
